INTRODUCTION
Anticitrullinated protein antibodies (ACPA) have been shown to be able to initiate and enhance arthritis in murine models of arthritis 1 2 and are able to activate Fc Receptor-positive cells 3 4 and the complement system, leading to the argument that they could play a role in disease pathogenesis. 5 The detection of ACPA, which is most commonly assessed by reactivity against cyclic citrullinated peptide (CCP)-2, is an accepted diagnostic tool for rheumatoid arthritis (RA). 6 ACPA are highly specifi c for RA, can be detected years before the fi rst clinical manifestation of RA 7 8 and are reported to be a good predictor for the development of RA. 9 Anti-CCP antibodies recognise multiple citrullinated peptides and proteins and are thus a collection of ACPA. 10 Some types of human leucocyte antigens (HLA) alleles, particularly HLA-DRB1 alleles encoding the shared epitope sequence, are known to be associated with RA susceptibility, 11 more specifi cally susceptibility to ACPA-positive RA. 12 ACPA-positive and ACPA-negative disease have been shown to be associated with different genetic and environmental risk factors, fuelling the hypothesis that different pathophysiological mechanisms are underlying these two separate disease subsets. 13 14 Next to isotype usage 15 and avidity, 16 the fi ne specifi city of an antibody response is also thought to contribute in determining its effi cacy. 17 It has been shown that ACPA can recognise a variety of citrullinated antigens, including citrullinated fi brinogen (cFib), α-enolase, 18 citrullinated vimentin (cVim) and citrullinated myelin-binding protein (cMBP)-the latter mimicking the Sa antigen. 19 20 Levels of specifi c ACPA are elevated in synovial fl uid, suggesting local antibody production and/or retention of ACPA at the site of infl ammation. 21 However, not all ACPA-positive sera will recognise all citrullinated antigens, as has been shown by analysing the reactivity against different citrullinated peptide antigens. 10 22 It has been shown that patients with RA display a much more extended citrullinated epitope recognition pattern compared to ACPA-positive fi rst-degree relatives without symptoms. 23 Indeed, epitope spreading with an increase in the recognition of citrullinated antigens occurs before the patients fulfi l the 1987 classifi cation criteria of RA. Differences in ACPA fi ne specifi city between patients having undifferentiated arthritis who do or do not develop RA after 1 year are already present at baseline. 24 Likewise, patients with arthralgia and with an extended ACPA repertoire have a higher risk of developing arthritis. 25 It is conceivable that a certain ACPA recognition profi le is associated with the emergence of certain clinical features and possibly pathogenicity, as has been shown in other autoimmune diseases. For example, in pemphigus the reactivity against different desmoglein epitopes is associated with different outcomes. 26 Here, we determined the association between the ACPA fi ne specifi city and phenotypic characteristics ▶ Additional data (supplementary fi gures) are published online only. To view the fi les please visit the journal online (http://ard.bmj.com/ content/71/2.toc) within ACPA-positive RA and investigated whether specifi c subsets of RA patients can be distinguished on the basis of their epitope recognition profi le.
MATERIALS AND METHODS

Patient population
All patients who fulfi lled the American College of Rheumatology 1987 revised criteria for the classifi cation of RA 27 within 1 year of follow-up from the Leiden Early Arthritis Clinic were analysed (n=661). The Leiden Early Arthritis Clinic is an inception cohort of patients with recent onset arthritis (symptoms duration, <2 years) that was started at the Department of Rheumatology of the Leiden University Medical Center in 1993 and was described in detail previously. 28 Sustained disease-modifying antirheumatic drug (DMARD)-free remission was defi ned as having no current use of DMARDs, no swollen joints and classifi cation as DMARD-free remission by the patients' rheumatologist. 29 
Anti-CCP2 assays
Total IgG anti-CCP2 was measured in baseline sera by ELISA (Immunoscan RA Mark 2; Eurodiagnostica, Arnhem, The Netherlands). Samples with a value >25 units/ml were considered positive according to the manufacturer's instructions. Individuals with antibodies against CCP2 were considered ACPA-positive. From patients with antibody levels reaching the plateau of the standard, we further diluted the serum to determine ACPA levels.
ACPA fi ne specifi city assays
ELISA assays were developed, as previously described, 30 against peptides derived from cVim, cFib and citrullinated α-enolase (cEno)5-20. Antibody reactivity against the citrullinated (Cit) and the uncitrullinated form of two linear peptides derived from vimentin (Vim 1-16: STCitS VSSS SYCitCit MFGG and Vim 59-74: VYAT CitSSA VCitLCit SSVP), two linear peptides derived from fi brinogen (Fibα 27-43: FLAE GGGV Cit GPR VVER H and Fibβ 36-52: NEEG FFSA CitGHR PLDK K) and one linear peptide derived from α-enolase (Eno 5-20: KIHA CitEIF DSCitG NPTV) were determined by ELISA as described previously 23 31 Citrullination of myelin basic protein (MBP) (Sigma-Aldrich, Zwijndrecht, Netherlands ) and the specifi c ELISA were performed as previously described. 20 Antibodies reactive with citrullinated MBP were determined in 1:100 diluted sera.
Although there are also other targets for ACPA, 32 33 we chose primarily to investigate epitopes from these proteins because they have been most consistently identifi ed as citrullinated autoantigens. 18 19 34 We analysed reactivity to citrullinated MBP, as its ELISA has been previously standardised to be the clinical equivalent (positive versus negative) of the original anti-Sa (cit-Vimentin) western blot assay. 20 Cut-off values for the citrulline-specifi c responses were calculated as previously described. 24 31 IgM-rheumatoid factor (RF), anti-CCP3 autoantibodies (IgA and IgG subforms) and antimutated citrullinated vimentin (MCV) autoantibodies were also measured by ELISA as described previously. 31 Sera were tested for antinuclear factor (ANF) using indirect immunofl uorescence at a 1:40 dilution on Hep-2000 cells (biomedical diagnostics).
Statistical analysis
Differences between groups were analysed with the MannWhitney test or the t test, or χ² test where appropriate. Association between anti-CCP2 antibody levels and number of peptides recognised was studied by linear regression of log-transformed anti-CCP2 antibody levels on number of recognised peptides. Principal component analyses (PCA) 35 were applied to covariance matrices and included the different fi ne specifi city epitopes. In order to normalise distributions, all variables were log-transformed concentration levels plus one. Based on scree plots and eigenvalues, components with an eigenvalue ≥0.4 were selected.
The association of the specifi c reactivities with baseline characteristics and joint damage over time was studied. Annual radiographs of hands and feet were assessed chronologically for radiographic damage according to the Sharp-van der Heijde score 36 by one experienced reader. For this, a repeated measurement analysis was applied. This method takes advantage of the longitudinal, repetitive character of the data and does not exclude patients with incomplete follow-up data, avoiding selection bias. In a multivariate normal regression model with radiological score as response variable, the effect of time was entered as factor to fi t the non-linear slope of joint destruction. The components were entered with an interaction term with time as continuous variable to test the effect of the components over time. Age, gender and inclusion period (a proxy for treatment strategy) were entered in the model to correct for possible confounding effects. Analyses were performed using SPSS version 17.0, and p values below 0.05 were considered to be statistically signifi cant.
Cluster analyses were used to identify subgroups of patients on the basis of their ACPA recognition profi le. Clustering illustrates the relationship between different patients and reactivities, as described by Eisen et al . 37 Hierarchical clustering was performed using average linkage clustering where patient correlation was performed centred and the reactivities uncentred. To illustrate the infl uence on anti-CCP2 level, we performed a supervised cluster analysis where the patients were fi xed and the reactivities correlated uncentred.
RESULTS
ACPA recognition profi le
Baseline characteristics of the 661 patients with RA who fulfi l the American College of Rheumatology criteria 1987 are shown in table 1 . To analyse whether the ACPA recognition profi le would allow for the identifi cation of specifi c antibody positive subgroups, we wished to perform cluster analyses as well as PCA to investigate whether specifi c subgroups can be identifi ed on the basis of epitope recognition. If so, such subgroups could then be used to analyse possible clinical association. First, we described patients on the basis of their ACPA status and their ability to recognise one specifi c citrullinated peptide (ie, cVim59-74 and cEno5-20). This analysis resulted in the identification of different subsets of patients ( fi gure 1A , B ). Combining the two reactivities against these two peptides resulted in more different subgroups ( fi gure 1C ). Remarkably, when using all nine reactivities included in this study, 64 subgroups could already be identifi ed ( fi gure 1D ). Dividing patients based on all tested reactivities (including cVim1-16, cVim59-74, cFibα27-43, cFibβ36-52, cEno5-20, MBP, MCV, mutated citrullinated vimentin; CCP2 and CCP3 resulted in 64 different subsets of patients, indicating a heterogeneous epitope recognition pattern. Depicted in black are patients negative for all the tested citrullinated antigens (fi gure 1D). CCP, cyclic citrullinated peptide; cEno, citrullinated α-enolase; cVim, citrullinated vimentin; cFib, citrullinated fi brinogen; MBP; myelin-binding protein.
Figure 2
The association between anti CCP2 levels and the recognition of multiple citrullinated epitopes. A supervised cluster analysis showed an association between the anti-CCP2 levels and number of recognised peptides (including cVim1-16, cFibα27-43, cEno5-20, cVim59-74, cMBP, cFibβ36-52, CCP3 and MCV, mutated citrullinated vimentin). There was no apparent association between levels and RF or ANF. Each column represents one patient, and each row, one tested fi ne specifi city peptide or protein. Depicted in red are patients being positive for the recognition of a specifi c reactivity; depicted in green are the patients who did not recognise that epitope. Depicted in grey are missing values. ANF, antinuclear factor; cEno, citrullinated α-enolase; CCP, cyclic citrullinated peptide; cFib, citrullinated fi brinogen; cVim, citrullinated vimentin; RF, rheumatoid factor.
These data show that within ACPA-positive patients, a large heterogeneity is present in the ACPA recognition profi le. More importantly, this large heterogeneity seems to preclude the identifi cation of specifi c subgroups. To investigate the possibility that specifi c peptide reactivities would cluster together, we generated a heatmap after an unsupervised hierarchical cluster analysis. A heatmap groups patients who resemble each other the most, based on their fi ne specifi city recognition repertoire. This analysis did not lead to the identifi cation of apparent subgroups of patients harbouring a specifi c ACPA recognition profi le (supplementary fi gure 1 ). Together, these analyses did not point to the presence of a clear pattern of recognition of citrullinated peptides by ACPA.
Interestingly, when we performed a similar analysis in a supervised manner by ordering patients on anti-CCP2 levels and subsequently analysed the recognition to specifi c peptides, an association was found between levels of anti-CCP2 antibodies and the number of recognised peptides by ACPA-positive patients with RA ( fi gure 2 ). The association between levels and the epitope recognition profi le was also confi rmed with a linear regression analysis (p<0.001). As control, the relation to RF or ANF status ( fi gure 2 ) was also analysed . In this case, no relation between anti-CCP2 levels and the antibody status of RF and ANF was found. Likewise, no association was found between the presence of antibodies against citrullinated epitopes and antibody levels against tetanus ( fi gure 3B ) or total IgG levels ( fi gure 3C ). Together, these data indicate that anti-CCP2 antibody levels specifi cally correlate with the number of citrullinated epitopes recognised by ACPA ( fi gure 3A ).
As our analyses described above did not identify defi ned subgroups, we performed PCA thereafter. PCA are an exploratory tool to unravel unknown trends in the data; however , this method also did not provide indications for the presence of patient subsets that can be grouped on the basis of the ACPA recognition profi le (data not shown). Together, these analyses show that within these reactivities, no apparent patterns of recognition of citrullinated peptides by ACPA are present.
ACPA fi ne specifi city and clinical characteristics
As outlined above, no specifi c subgroups of patients could be identifi ed based on the presence of different ACPA characteristics. Therefore, we wished to analyse associations between baseline characteristics and the recognition of specifi c epitopes. To determine whether the baseline characteristics are associated with the recognition of specifi c citrullinated epitopes, we performed these analyses in the ACPA-positive stratum only. In doing so, we control the possibility that the results described above are explained by the known association between baseline characteristics and ACPA status, rather than by an infl uence of specifi c epitope recognition on baseline characteristics (ie, all ACPA reactivities are almost exclusively found within the ACPApositive stratum). We observed essentially no association with any of the reactivities in relation to any of the baseline characteristics tested ( fi gure 4 and supplementary fi gure 2 ). Although an association between reactivity against anti-cMBP-reactivity and C reactive protein (CRP) was observed (p=0.008), this association did not remain after the Bonferroni correction for multiple testing ( fi gure 4 ). In line with these data, patients with an extended fi ne specifi city repertoire (defi ned by the recognition of more than two citrullinated epitopes) also did not display signifi cant differences in baseline characteristics compared to ACPA-positive patients recognising fewer peptides ( fi gure 4 ), as the difference in CRP levels (p=0.018) could not withstand correction for multiple testing.
Another goal for making subgroups is to identify patients who will reach remission or will develop more joint destruction over time. Therefore, we wished to analyse sustained DMARD-free Figure 3 Association between CCP2 level and number of citrullinated epitopes recognised. The number of epitopes recognised was positively associated with the anti-CCP2 levels (fi gure 3A). This association is citrulline-specifi c rather than antibody-level-specifi c, as it was not found for antitetanus antibody levels (fi gure 3B). Also, total-IgG levels were not associated with the number of epitopes recognised by patients with RA (fi gure 3C). Graphs are depicted with mean±SEM. Epitopes included in these analyses were cVim1-16, cVim59-74, cFibα27-43, cFibβ36-52, cEno5-20, cMBP, MCV, mutated citrullinated vimentin; CCP2 and CCP3. CCP, cyclic citrullinated peptide; cEno, citrullinated α-enolase; cFib, citrullinated fi brinogen; cMBP, citrullinated myelin-binding protein; cVim, citrullinated vimentin; RA, rheumatoid arthritis.
group.bmj.com on October 2, 2012 -Published by ard.bmj.com Downloaded from remission and joint damage over time within the ACPA-positive stratum. Only nine out of 306 ACPA-positive patients with RA achieved remission. As a consequence of this low number of patients, we did not perform further analyses into the association of the ACPA recognition profi le and remission. Recently, we have shown that different fi ne specifi cities or an extended ACPA recognition profi le was not associated with joint destruction over time. 38 We now extended these fi ndings by analysing additional citrullinated epitopes, but this analysis also did not indicate an association between the recognition of a specifi c citrullinated epitope with radiological progression. Nonetheless, it is possible that an association exists for another, not in our study Figure 4 The association between epitope recognition and baseline characteristics. We observed essentially no association with any of the reactivities in relation to any of the baseline characteristics tested. An association was found between the recognition of cMBP and higher CRP levels at baseline (p=0.008) and recognition of more citrullinated peptides with CRP levels (p=0.018). However, after correction for multiple testing, no association between the recognition of specifi c citrullinated epitopes and baseline characteristics remained. Depicted are the mean and the SD between different citrullinated epitopes and baseline characteristics within ACPA-positive patients. Age of inclusion is depicted in years, swollen joint count with number of swollen joints, morning stiffness in min, ESR in mm/h, CRP in mg/l and RF in percentage positivity. ACPA, anticitrullinated protein antibodies; cMBP, citrullinated myelin-binding protein; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; SJC, swollen joint count.
Figure 5
Rate of joint destruction over time and anti-CCP2 levels. Anti-CCP2 positive patients developed signifi cantly more joint destruction over time (p <0.001) compared to anti-CCP2-negative patients. Within the anti-CCP2-positive patients the rate of joint destruction between patient with high levels (>620 arbitrary units (AU) ) and low levels (<620AU) did not differ (p=0.66) . The ACPA-positive patients were divided into two groups based on the median of 620 AU. ACPA, anticitrullinated protein antibodies; CCP, cyclic citrullinated peptide.
-CCP2 levels and the number of peptides recognised by patients ( fi gures 2 and 3 ). Therefore, we wished to use anti-CCP2 levels as a proxy for the peptides that we did not analyse. Intriguingly, we did not observe an association between rate of joint destruction over time and the anti-CCP2 levels within the ACPA-positive patients (p=0.66) ( fi gure 5 ).
Together, our data indicate that although the ACPA recognition profi le is highly diverse, the number of epitopes recognised correlates with ACPA level. Interestingly, the recognition of these citrullinated peptides, irrespective of their differences in peptide-backbone structure, all correlated with similar clinical characteristics.
DISCUSSION
Epitope spreading is a phenomenon in which the (auto)immune response is extended to include new epitopes within the same molecule or towards different molecules and is thought to be involved in disease onset of autoimmune disorders. For example, pemphigus is one of the most clearly defi ned autoimmune diseases mediated by autoantibodies. The involvement of epitope spreading in pemphigus pathogenesis was fi rst demonstrated in endemic pemphigus foliaceous. 26 Subjects in the preclinical stage harbour antibodies recognising different epitopes on desmoglein 1 compared to patients after disease onset. 39 In several cases of pemphigus, it has been described that intermolecular epitope shifting occurs along with the transition of pemphigus phenotype.
In RA, the association between epitope spreading in a predisease phase with RA development had been described as well. For example, it has been shown that epitope spreading of the ACPA response occurs before clinical disease onset and that it is associated with the disease course of early arthritis. 23 Likewise, at time of disease onset, ACPA-positive patients with undifferentiated arthritis who will subsequently develop RA and those that will not already have an immunological distinct immune response, although these differences were not confi ned to specifi c citrullinated epitopes. The relevance of epitope spreading before disease onset raised the question as to whether a different epitope recognition pattern would be associated with different clinical phenotypes as has been described in pemphigus. This question was also based upon the fi ndings that HLA shared epitope alleles predispose for the development of antibodies against some but not for other citrullinated epitopes, suggesting that reactivity towards some epitopes plays a more relevant role than others in disease pathogenesis. 30 40 41 Here, we investigated whether specifi c subsets of RA patients could be distinguished on the basis of an autoimmune response to specifi c citrullinated epitopes and investigated the effects of the ACPA fi ne specifi city on clinical features of RA. The analyses were performed within the ACPA-positive stratum to exclude the infl uence of ACPA status on disease outcome, as published before. 42 As subgrouping patients based on their epitope recognition profi le could be potentially useful to get more homogenous patient groups, we analysed different recognition profi les in detail. Unsupervised clustering of patients based on their epitope recognition resulted in many different subgroups, making it unrealistic to analyse all those subgroups in detail. Therefore we analysed the data with the use of several methods to obtain indications as to whether specifi c patient groups can be formed based upon the (cumulative) occurrence of specifi c antibody reactivities. The PCA did not point to specifi c reactivities as a discriminative factor within the variables. Likewise, the cluster analysis also did not result in clustering of specifi c patients.
These data suggest that the recognition profi le of patients with RA displays a large heterogeneity and that patients are not characterised by a unique and specifi c epitope recognition pattern.
The data described above might not be surprising, given the observation that even the baseline differences between ACPApositive and ACPA-negative patients with RA are rather small. Nonetheless, these latter subgroups differ considerably with respect to disease course as measured by radiological progression. 42 We feel that it is unlikely that ACPA fi ne specifi city within ACPA-positive disease will have a similar impact as found for ACPA status within RA. This notion is supported by our observation that a similar rate of joint destruction is observed between ACPA-positive patients with high-and low-baseline anti-CCP2 levels as proxy for the extent of epitope recognition. Likewise, recent observations made by our group and others analysing the possible connection between reactivity against a specifi c citrullinated epitope provided similar indications. 38 43 Remarkably, these fi ndings contrast observations made in early/predisease RA, as it has been shown that ACPApositive subjects who are still healthy or have early arthritis are more likely to develop arthritis when harbouring a more extended generalised citrullinated epitope recognition pattern. 24 The reason why 'maturation' of the ACPA response with respect to its epitope recognition profi le is associated with transition to disease but, once disease is established, not with disease outcome, is not known. However, it is tempting to speculate that once a certain threshold is reached, disease manifestations become apparent. In case ACPA would be involved in disease pathogenesis, it is conceivable that over this threshold, higher levels or a more extended recognition profi le does not contribute further to disease progression, as the response is already maximally involved in creation of the harmful infl ammatory milieu underlying the signs and symptoms associated with RA.
Although our data indicate that no clear link exists between clinical features and autoimmunity against specifi c citrullinated antigens, we cannot exclude that antibodies against other citrullinated antigens will correlate with clinical outcome once the disease has emerged. Obviously this could lead to two phenotypically different subgroups. However, we feel that it is more likely that inclusion of more citrullinated epitopes will result in more subgroups as analysing nine reactivities already led to a division into 64 subgroups, each displaying a unique ACPA recognition profi le. Likewise, we cannot exclude that associations could be found with a more extended samples size; however, based on our sample size, the effect would still remain small, and increasing sample size further will unlikely result in a meaningful clinical difference.
Altogether, our data indicate that the epitope recognition profi le is highly diverse. The recognition of different citrullinated peptides at baseline correlated with similar clinical characteristics, irrespective of differences in peptide-backbone structure, indicating that the breaking of tolerance towards citrullinated proteins as such provides more information than the recognition of a particular peptide or set of peptides.
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